Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Date:5/13/2009

1,411 3,604 TOTAL OPERATING EXPENSES 2,986 33,451 OPERATING INCOME (LOSS) 344 (33,252) OTHER INCOME (EXPENSE): Interest and other income (expense), net 107 (1,203) INCOME (LOSS) FROM CONTINUING OPERATIONS 451 (34,455) Loss from discontinued operations -- (81) NET INCOME (LOSS) $ 451 $(34,536) NET INCOME (LOSS) PER COMMON SHARE Continuing operations $ 0.01 $ (0.79) Discontinued operations -- (--)* Basic and diluted net income (loss) per common share $ 0.01 $ (0.79) SHARES USED IN COMPUTING NET (INCOME) LOSS PER COMMON SHARE Basic 47,853,895 43,718,077 Diluted 48,050,220 43,718,077 * Amount less than one cent.

    Balance Sheet Information:

                                           March 31, 2009   December 31, 2008*
                                               (unaudited)
    Cash, cash equivalents, interest
     receivable and short-term investment
     securities                                  $15,446             $15,467
    Long-term investment securities                7,117               7,185
    Total assets                                  26,445              26,634
    Accumulated deficit                         (331,467)           (331,918)
    Stockholders' deficit                           (467)             (1,489)

    * Condensed from audited financial statements.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
5. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... 2015 EHO offers a suite of ... gives hospices the ability to manage their drug-spend for ... business model, EHO has been able to compete with ... clients and survive among the giants of the industry. ... three years ago, it has simplified the way hospices ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Cyclist ... tour, “Wheels for the World 2015: Piles of ... to raise awareness about hemophilia and encourage individuals ... Life. , Save One Life supports nearly ... eleven developing countries through direct sponsorships, scholarships and ...
(Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with a new hanging ... signs ; making what was formerly an elite expensive ... points at a usual height of 16’-20’ are easily seen ... are very unique and more visible than the largest exhibits. ... labor and rigging the costs far outweigh the benefit of ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2
... a medical conference that takes place entirely online, announces participation of ... Prevention Center. Dr. Kaskel to present "Improved Patient Outcomes and ... ... MA (PRWEB) February 18, 2009 -- CardioCareLive , the first ...
... 18 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... company that controls,and operates pharmaceutical companies in ... that contractually controlled Beijing Liang Fang,Pharmaceutical Co., ... rights,transfer contract with Beijing Yipuan Bio-Medical Technology ...
... Has Resisted Well, - Continued Reduction in Net Debt, In millions of euros ... 168.4 ... 19.3 26.8, EBITDA margin ... Current operating income* 4.6 12.0, ...
... to educate, inform, and empower the people of Chicago, ... its 25-minute live call-in show, "Community Health," on Chicago ... 6:00 PM on Channel 21. Monday,s program, with ... the Balancing Center in Chicago will discuss the health ...
... Michael J. Fox Foundation for Parkinson,s Research awarded ... to develop neuroimaging technologies that would allow scientists ... protein in the living human brain. Such technologies ... and treatment of PD. Investigators could more accurately ...
... and survival is poorer, new report finds , , WEDNESDAY, ... rates continue to decline, an American Cancer Society report ... more advanced stages of cancer than whites, the report,s ... each stage of diagnosis of most types of cancers. ...
Cached Medicine News:Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 3Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 2Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 3Health News:Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug 4Health News:PCAS: 2008 Results 2Health News:PCAS: 2008 Results 3Health News:Save Your Money and Your Health 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 3Health News:Cancer Death Rates Decline Among Blacks, But Disparities Linger 2Health News:Cancer Death Rates Decline Among Blacks, But Disparities Linger 3
(Date:5/29/2015)... -- Fair Rate Funding, a leader in TV mesh lawsuit ... Delaware found Thursday that Boston Scientific,s Pinnacle ... prolapse (POP) and Stress Urinary Incontinence (SUI) in women, ... design flaws from the plaintiff, Deborah Barba . ... Transvaginal mesh, also known as TV mesh or ...
(Date:5/29/2015)... , May 29, 2015 Actinobac Biomed, ... originally funded with investments from Foundation Venture Capital Group ... Bio International 2015 as part of the Start-Up Stadium ... FVCG President James M. Golubieski . ... biotechnology industry, will be held in Philadelphia ...
(Date:5/29/2015)... 29, 2015  Dr. Yair Walzer has added ... health issues often caused by menopause. The MonaLisa Touch™, an ... received FDA clearance in 2014. Dr. Walzer is one of ... offer the special fractional CO 2 laser specifically designed ... In 2010 there were greater than 46M ...
Breaking Medicine Technology:TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict. 2TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict. 3Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2
... WALTHAM, Mass., Nov. 2 According to ... technology market intelligence, the atrial fibrillation device market will ... Europe, and Japan. MRG,s Global Markets for Atrial ... many patients will be treated with electrophysiology technology and ...
... Decision Resources, one of the world,s ... issues, finds that 98 percent of surveyed rheumatologists indicate ... the treatment of rheumatoid arthritis following the agent,s expected ... the drug, more than 60 percent of these rheumatologists ...
Cached Medicine Technology:Global Atrial Fibrillation Device Market to Grow by Almost 10% Through 2013 2Global Atrial Fibrillation Device Market to Grow by Almost 10% Through 2013 3Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis 2Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis 3
Hydraulic ophthalmic stretcher for eye surgery....
... a staining solution for cataract surgery. ... performing a safe phaco-emulsification procedure. Inadequate ... may result in an incomplete capsulorhexis, ... radial capsule tears and associated complications. ...
Rhex-ID (Trypan Blue 0.8 mg)....
Unmatched versatility for hemostasis wherever needed. Can be applied to suit your needs....
Medicine Products: